# A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)

> **NCT05347225** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 12 (estimated)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** Nemtabrutinib

## Key facts

- **NCT ID:** NCT05347225
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-09
- **Primary completion:** 2027-04-30
- **Final completion:** 2028-12-29
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05347225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05347225, "A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05347225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*